Other Shoe Drops; Tranzyme Posts Second TZP-102 Miss
By Catherine Shaffer
Staff Writer
Staff Writer
Monday, December 17, 2012
Just one month after devastating news that its gastroparesis candidate, TZP-102, missed its endpoint in a Phase IIb trial, Tranzyme Pharma Inc., of Research Triangle Park, N.C., reported that its a second Phase IIb trial of the same drug was being discontinued after an interim futility analysis showed a large placebo effect and no treatment effect.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.